Payment overview · 2025
General Payments
$473.40
17 reported records · 9 companies
Healthcare provider profile · identity verified
Jonathan Brisson, D.O.
Allopathic & Osteopathic Physicians|Internal Medicine · FORT MYERS, FL · NPI 1265712160
Verified facts
What the public records show
CMS Open Payments records show Jonathan Brisson, D.O. received $473.40 in general payments during 2025 across 17 reported records.
Lundbeck LLC accounted for 26.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Trelegy Ellipta.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lundbeck LLC | Unresolved — no canonical attribution shown | $125.24 | 26.5% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $85.92 | 18.1% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $70.77 | 14.9% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $59.37 | 12.5% | 3 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $44.41 | 9.4% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $38.60 | 8.2% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $18.74 | 4.0% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $15.38 | 3.2% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $14.97 | 3.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $473.40 | 17 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $125.24 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $59.37 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $54.14 | 2 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $44.41 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $38.60 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $31.78 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $18.74 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $18.74 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $17.84 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $15.38 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $14.97 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
41 | 11 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
51 | 18 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
21 | 21 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 536 | 171 |
| Amlodipine Besylate | Amlodipine Besylate | 332 | 102 |
| Levothyroxine Sodium | Levothyroxine Sodium | 272 | 74 |
| Lisinopril | Lisinopril | 271 | 75 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 266 | 87 |
| Omeprazole | Omeprazole | 178 | 55 |
| Losartan Potassium | Losartan Potassium | 161 | 45 |
| Metoprolol Succinate | Metoprolol Succinate | 160 | 48 |
| Metformin Hcl Er | Metformin Hcl | 139 | 46 |
| Sertraline Hcl | Sertraline Hcl | 136 | 45 |
| Tamsulosin Hcl | Tamsulosin Hcl | 127 | 41 |
| Allopurinol | Allopurinol | 125 | 34 |
| Pantoprazole Sodium | Pantoprazole Sodium | 118 | 41 |
| Simvastatin | Simvastatin | 113 | 36 |
| Gabapentin | Gabapentin | 102 | 32 |
| Metoprolol Tartrate | Metoprolol Tartrate | 100 | 31 |
| Glipizide Er | Glipizide | 99 | 31 |
| Metformin Hcl | Metformin Hcl | 98 | 29 |
| Hydrochlorothiazide | Hydrochlorothiazide | 93 | 30 |
| Azithromycin | Azithromycin | 88 | 77 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 86 | 26 |
| Montelukast Sodium | Montelukast Sodium | 85 | 27 |
| Ezetimibe | Ezetimibe | 71 | 21 |
| Trazodone Hcl | Trazodone Hcl | 70 | 25 |
| Fluticasone Propionate | Fluticasone Propionate | 61 | 25 |
| Escitalopram Oxalate | Escitalopram Oxalate | 54 | 17 |
| Eliquis | Apixaban | 51 | 18 |
| Methylprednisolone | Methylprednisolone | 51 | 43 |
| Carvedilol | Carvedilol | 50 | 14 |
| Jardiance | Empagliflozin | 50 | 11 |
| Atenolol | Atenolol | 49 | 14 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 48 | 14 |
| Prednisone | Prednisone | 48 | 22 |
| Famotidine | Famotidine | 47 | 18 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 43 | 19 |
| Buspirone Hcl | Buspirone Hcl | 42 | 17 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 42 | 14 |
| Ozempic | Semaglutide | 41 | 11 |
| Meloxicam | Meloxicam | 39 | 16 |
| Synthroid | Levothyroxine Sodium | 38 | 11 |
| Clopidogrel | Clopidogrel Bisulfate | 37 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 37 | 12 |
| Torsemide | Torsemide | 37 | 19 |
| Bupropion Xl | Bupropion Hcl | 33 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 32 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 29 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 27 | 11 |
| Potassium Chloride | Potassium Chloride | 27 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 26 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 26 | suppressed |
| Finasteride | Finasteride | 25 | suppressed |
| Ibuprofen | Ibuprofen | 25 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 24 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 24 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 24 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 24 | 14 |
| Dexamethasone | Dexamethasone | 23 | 23 |
| Alprazolam | Alprazolam | 21 | 13 |
| Benazepril Hcl | Benazepril Hcl | 21 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 21 | 21 |
| Cephalexin | Cephalexin | 20 | 17 |
| Estradiol | Estradiol | 20 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 19 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 19 | 13 |
| Amitriptyline Hcl | Amitriptyline Hcl | 18 | suppressed |
| Spironolactone | Spironolactone | 18 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 17 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 17 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 17 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 17 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 17 | suppressed |
| Ramipril | Ramipril | 17 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 16 | 14 |
| Doxazosin Mesylate | Doxazosin Mesylate | 16 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 16 | 13 |
| Zolpidem Tartrate | Zolpidem Tartrate | 16 | suppressed |
| Celecoxib | Celecoxib | 15 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 15 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 15 | 12 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 15 | suppressed |
| Lansoprazole | Lansoprazole | 15 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 15 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 15 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 14 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 14 | suppressed |
| Levetiracetam | Levetiracetam | 14 | suppressed |
| Trulicity | Dulaglutide | 14 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 13 | suppressed |
| Furosemide | Furosemide | 13 | suppressed |
| Hydrocortisone | Hydrocortisone | 13 | suppressed |
| Memantine Hcl | Memantine Hcl | 13 | suppressed |
| Topiramate | Topiramate | 13 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 13 | suppressed |
| Valsartan | Valsartan | 13 | suppressed |
| Acyclovir | Acyclovir | 12 | suppressed |
| Glimepiride | Glimepiride | 12 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 12 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 12 | suppressed |
| Chlorthalidone | Chlorthalidone | 11 | suppressed |
| Enalapril-Hydrochlorothiazide | Enalapril/Hydrochlorothiazide | 11 | suppressed |
| Glipizide | Glipizide | 11 | suppressed |
| Mounjaro | Tirzepatide | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $473.40 · 17 records | Lundbeck LLC | AREXVY, CAPVAXIVE, Cologuard Collection Kit, EVENITY, NEXLETOL, NURTEC ODT, REXULTI, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, ZAVZPRET, ZENPEP | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Trelegy Ellipta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error